Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Chronic Kidney Disease | Research article

Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

Authors: Xiaole Su, Bingjuan Yan, Lihua Wang, Jicheng Lv, Hong Cheng, Yipu Chen

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

The benefits and risks of antiplatelet therapy for patients with chronic kidney disease (CKD) remain controversial. We undertook a systematic review and meta-analysis to investigate the effects of antiplatelet therapy on major clinical outcomes.

Methods

We systematically searched MEDLINE, Embase, and the Cochrane Library for trials published before April 2019 without language restriction. We included rrandomized controlled trials that involved adults with CKD and compared antiplatelet agents with controls.

Results

Fifty eligible trials that included at least one event were identified, providing data for 27773patients with CKD, including 4518 major cardiovascular events and 1962 all-cause deaths. Antiplatelet therapy produced a 15% (OR, 0.85; 95% CI 0.74–0.94) reduction in the odds of major cardiovascular events (P = 0.002), a 48% reduction for access failure events (OR, 0.52; 95% CI, 0.31–0.73), but had no significantly effect on all-cause death (OR, 0.87; 95% CI, 0.71–1.01) or kidney failure events (OR, 0.87; 95% CI, 0.32–1.55). Adverse events were significantly increased by antiplatelet therapy, including major (OR, 1.33; 95% CI, 1.11–1.59) or minor bleeding (OR, 1.66; 95% CI, 1.27–2.05). Among every 1000 persons with CKD treated with antiplatelet therapy for 12 months, 23 major cardiovascular events will be prevented while nine major bleeding events will occur.

Conclusions

Major prevention with antiplatelet agents (cardiovascular events and access failure), might outweigh the risk of bleeding, and there seemed to be an overall net benefit. Individual evaluation and careful monitoring are required.
Appendix
Available only for authorised users
Literature
1.
James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375(9722):1296–309.PubMedCrossRef
2.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRef
3.
Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333(7577):1047.PubMedPubMedCentralCrossRef
4.
McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008;156(2):277–83.PubMedCrossRef
5.
Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423–9.PubMedCrossRef
6.
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int. 2012;82(8):840–56. PMID: 22895519.PubMedCrossRef
7.
Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci. 1998;316(2):94–104.PubMed
8.
Francis ME, Eggers PW, Hostetter TH, Briggs JP. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int. 2004;66(1):303–12.PubMedCrossRef
9.
Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis. 2013;61(1):112–22.PubMedCrossRef
10.
Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the reduction of events during observation (CREDO) trial. Am Heart J. 2008;155(4):687–93.PubMedCrossRef
11.
Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359–63.PubMedCrossRef
12.
Rouzrokh M, Abbasi MR, Mirshemirani AR, Sobhiyeh MR. The effect of antiplatelet drugs on the patency rate of Arterio-venous fistulae in hemodialysis patients. Iran J Pharm Res. 2010;9(4):451–7.PubMedPubMedCentral
13.
James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.PubMedCrossRef
14.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.PubMedCrossRef
15.
Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009;360(21):2191–201.PubMedPubMedCentralCrossRef
16.
Krause MW, Massing M, Kshirsagar A, Rosamond W, Simpson RJ Jr. Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease. Ren Fail. 2004;26(6):715–25.PubMedCrossRef
17.
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201–8.PubMedCrossRef
18.
19.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentralCrossRef
20.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentralCrossRef
21.
Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011;305(10):1008–17.PubMedCrossRef
22.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.PubMedCrossRef
23.
Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med. 2002;21(11):1601–23.PubMedCrossRef
24.
Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med. 2014;160(4):267–70.PubMedCrossRef
25.
Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;4:434–55.
26.
27.
Harville DA. Maximum likelihood approaches to variance component estimation and to related problems. J Am Stat Assoc. 1977;358:320–38.CrossRef
28.
Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22(17):2693–710.PubMedCrossRef
29.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: metaanalysis in context. 2nd ed. London: BMJ Books; 2001. p. 285–312.CrossRef
30.
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–8.PubMedPubMedCentralCrossRef
31.
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445–59.PubMedCrossRef
32.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. PMID: 11786451.PubMedCentralCrossRef
33.
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;(2):Cd008834. PMID: 23450589.
34.
Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956–65.PubMedCrossRef
35.
Anderson M, Dewar P, Fleming LB, Hacking PM, Morley AR, Murray S, et al. A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clin Nephrol. 1974;2(3):93–9.PubMed
36.
Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr. 1974;52(7):348–9.PubMedCrossRef
37.
Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. N Engl J Med. 1974;290(6):304–6.PubMedCrossRef
38.
Michie DD, Wombolt DG. Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Curr Ther Res Clin Exp. 1977;22(1):196–204.
39.
Donadio JV, Anderson CF, Mitchell JC. A controlled trial of platelet inhibitor drugs in membranoproliferative glomerulonephritis (MPGN). Kidney Int. 1978;14(6):649.
40.
Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med. 1979;301(11):577–9.PubMedCrossRef
41.
Kauffman HM, Adams MB, Hebert LA, Walczak PM. Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplant Proc. 1980;12(2):311–4.PubMed
42.
Kobayashi K, Maeda K, Koshikawa S. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis - a multicenter collaborative double-blind study. Thromb Res. 1980;20(2):255–61.PubMedCrossRef
43.
Ell S, Mihinduk JC, O’Brien JR, Polak A, Vernham G. Ticlopidine in the prevention of blockage of fistulae and shunts. Haemostasis. 1982;12:180.
44.
Donadio JV, Anderson CF, Mitchell JC, Holley KE, Ilstrup DM, Fuster V. Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy. Kidney Int. 1983;23:121.
45.
Donadio JV Jr, Anderson CF, Mitchell JC 3rd, Holley KE, Ilstrup DM, Fuster V, et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med. 1984;310(22):1421–6.PubMedCrossRef
46.
Nyberg G, Larsson O, Westberg NG. A platelet aggregation inhibitor - ticlopidine - in diabetic nephropathy: a randomized double-blind study. Clin Nephrol. 1984;21(3):184–7.PubMed
47.
Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs. 1985;9(1):61–3.PubMedCrossRef
48.
Grontoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol. 1985;19(1):55–7.CrossRef
49.
Schulze R, Langkopf B, Sziegoleit W. The effect of dipyridamole on the results of allogenic kidney transplantation. Z Urol Nephrol. 1990;83(5):255–9.PubMed
50.
Creek R. Ticlopidine. Patency of haemodialysis access sites. Guildford: Sanofi Winthrop; 1990. [Internal report]
51.
Quarto Di Palo F, Elli A, Rivolta R, Parenti M, Palazzi P, Zanussi C. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplant Proc. 1991;23(1 Pt 2):969–71.PubMed
52.
Ferris FL, Kassoff A, Buzney SM, McMeel JW, Weiter JJ, Doyle GJ, et al. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy Study report 14. JAMA. 1992;268(10):1292–300.CrossRef
53.
Taber T, Maikranz P, Haag B, Dilley R, Gaylord G. Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (lmd), but not by aspirin (asa). J Am Soc Nephrol. 1992;3:397.
54.
Middleton DA, Deichsel G. The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Berlin: Boehringer Ingelheim; 1992. [Internal report]
55.
Kooistra MP, van Es A, Marx JJ, Hertsig ML, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant. 1994;9(8):1115–20.PubMedCrossRef
56.
Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int. 1994;45(5):1477–83.PubMedCrossRef
57.
Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrol Dial Transplant. 1994;9(6):619–22.PubMedCrossRef
58.
Study E. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med. 1994;330(14):956–61.CrossRef
59.
Mileti M, De Petri G, Bacchi M, Ogliari V, Pecchini F, Bufano G, et al. A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. J Nephrol. 1995;8(3):167–72.
60.
Frasca GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrol Dial Transplant. 1996;11(2):392–3.PubMedCrossRef
61.
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336(24):1689–96.CrossRef
62.
The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349(9063):1422–8. PMID: 9164315.
63.
Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA organization and randomized trial (RAPPORT) investigators. Circulation. 1998;98(8):734–41.PubMedCrossRef
64.
Cheng IKP, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HWD. A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology. 1998;4(1–2):19–26.CrossRef
65.
Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, et al. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes. 1998;47(3):423–30.PubMedCrossRef
66.
Gröntoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in AV-fistula surgery in uremia. Scand J Urol. 1998;32(4):276–83.CrossRef
67.
The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352(9122):87–92.CrossRef
68.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with Eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339(7):436–43.CrossRef
69.
Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 1999;99:2371–7.PubMedCrossRef
70.
Baigent C. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study. J Am Soc Nephrol. 2002;13:437a.
71.
Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the platelet receptor inhibition in ischemic syndrome Management in Patients Limited by unstable signs and symptoms (PRISM-PLUS) trial. Circulation. 2002;105(20):2361–6.PubMedCrossRef
72.
Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol. 2002;36(2):145–8.CrossRef
73.
Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14(9):2313–21.PubMedCrossRef
74.
Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom heart and renal protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473–84.PubMedCrossRef
75.
Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro give similar efficacy outcome (TARGET) trial. Am Heart J. 2005;149(5):869–75.PubMedCrossRef
76.
Abdul-Rahman IS, Al-Howaish AK. Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong J Nephrol. 2007;9(1):23–30.CrossRef
77.
Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Prev Cardiol. 2007;14(2):312–8.CrossRef
78.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.PubMedCrossRef
79.
Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164–71.PubMedPubMedCentralCrossRef
80.
Ogawa S, Mori T, Nako K, Ishizuka T, Ito S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clin J Am Soc Nephrol. 2008;3(2):362–8.PubMedPubMedCentralCrossRef
81.
Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess improvement in therapeutic outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-thrombolysis in myocardial infarction (TIMI) 38 substudy. Am Heart J. 2009;158(3):e21–6.PubMedCrossRef
82.
Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57–61.PubMedPubMedCentralCrossRef
83.
Luk AOY, So WY, Ozaki R, Yeung CY, Choi K, Kong APS, et al. A randomized, double-blind, placebo-controlled study of cilostazol in the treatment of nephropathy in Chinese patients with type 2 diabetes. In: Diabetes; 2010.
84.
Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, et al. Use of aspirin associates with longer primary patency of hemodialysis grafts. J Am Soc Nephrol. 2011;22(4):773–81.PubMedPubMedCentralCrossRef
85.
Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011;34(2):280–5.PubMedPubMedCentralCrossRef
86.
87.
Dash A, Maiti R, Bandakkanavar TKA, Bhaskar A, Prakash J, Pandey BL. Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. Int J Prev Med. 2013;4(8):902–10.PubMedPubMedCentral
88.
Jiao XM, Jiao XJ, Zhang XG, Xu XP, Wu JX, Yao L, et al. Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chin Med J. 2013;126(22):4395–6.PubMed
89.
Mozafar M, Samsami M, Sobhiyeh MR, Jabbehdari S, Zavareh MF. Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourol Mon. 2013;5(2):762–5.PubMedPubMedCentralCrossRef
90.
Tang WH, Lin FH, Lee CH, Kuo FC, Hsieh CH, Hsiao FC, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine. 2014;45(2):293–301.PubMedCrossRef
91.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.PubMedCrossRef
92.
Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, et al. Aspirin for primary prevention of cardiovascular Disease and renal Disease progression in chronic kidney Disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255–63.PubMedCrossRef
93.
Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M, Kuder J, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37(4):400–8.PubMed
94.
Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807–17.PubMedCrossRef
95.
Bossard M, Jeger R. Prolonged dual antiplatelet therapy in renal failure: a challenging trade-off. J Thorac Dis. 2015;7(12):E625–E8.PubMedPubMedCentral
Metadata
Title
Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Authors
Xiaole Su
Bingjuan Yan
Lihua Wang
Jicheng Lv
Hong Cheng
Yipu Chen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1499-3

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue

Research article

Investigation of the variants at the binding site of inflammatory transcription factor NF-κB in patients with end-stage renal disease

Research article

Time-varying serum albumin levels and all-cause mortality in prevalent peritoneal dialysis patients: a 5-year observational study

Research article

Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study

Research article

Arg913Gln variation of SLC12A3 gene is associated with diabetic nephropathy in type 2 diabetes and Gitelman syndrome: a systematic review

Case report

A case report of successfully treated nephrotic syndrome after renal angioplasty

Research article

miR-10b suppresses cell invasion and metastasis through targeting HOXA3 regulated by FAK/YAP signaling pathway in clear-cell renal cell carcinoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits